Quick access to up-to-date company information.
Volasertib, Boehringer Ingelheim’s Investigational Oncology Compound, is Granted Orphan Drug Designation for Acute Myeloid Leukemia in the U.S. and EU
For U.S. Media Only
Boehringer Ingelheim Reports 2013 Fiscal Year Results
Boehringer Ingelheim and Eli Lilly and Company Announce New Drug Application Filing in the U.S. for the Combination Tablet of Empagliflozin and Linagliptin
FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism
Nearly 80 Percent of Cardiologists Say Ischemic Stroke Risk Reduction is Their Primary Goal in Non-valvular Atrial Fibrillation Treatment, New Survey Shows
900 Ridgebury Rd.P.O. Box 368Ridgefield, CT 06877